Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 7/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP4 | P49662 | 1/20 | 0.43 |
| ▸ | CASP5 | P51878 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6100319 | 0.90 | HTT (0.49) | GLP1RHTTNPC1MAPTRAB9A | |
| SCHEMBL6100140 | 0.87 | NPC1 (0.59) | HTTNPC1MAPTRAB9AHRH3 | |
| SCHEMBL6096996 | 0.86 | KDM4E (0.52) | HTTNPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL6101716 | 0.84 | GLP1R (0.42) | GLP1RHTTNPC1MAPTRAB9A | |
| SCHEMBL6099099 | 0.83 | HTT (0.47) | GLP1RHTTNPC1MAPTRAB9A | |
| SCHEMBL6099758 | 0.82 | HRH3 (0.45) | GLP1RHTTNPC1MAPTRAB9A | |
| SCHEMBL6097756 | 0.82 | HTT (0.52) | HTTNPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL6099216 | 0.82 | GLP1R (0.41) | GLP1RHTTNPC1MAPTRAB9A | |
| SCHEMBL6099911 | 0.80 | ALDH1A1 (0.47) | HTTNPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL6099980 | 0.80 | ALDH1A1 (0.61) | GLP1RHTTNPC1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7009051-B2 | 4-(2-pyridyl) piperazines having 5HT7 receptor agonist activity | PFIZER INC (US) | 2006-03-07 | — | — | US | claimed |
| US-20040014769-A1 | 4-(2-Pyridyl)piperazines having 5HT7 receptor agonist activity | PFIZER INC. | 2004-01-22 | — | — | US | claimed |
| EP-1254905-B1 | 4-(2-Pyridyl)piperazines having 5HT7 receptor agonist activity | PFIZER PROD INC (US) | 2003-12-17 | — | — | EP | claimed |
| US-20030008880-A1 | 4-(2-Pyridyl) piperizines having 5HT7 receptor agonist activity | PFIZER INC. | 2003-01-09 | — | — | US | claimed |
| EP-1254905-A1 | 4-(2-Pyridyl)piperazines having 5HT7 receptor agonist activity | Pfizer Products Inc. (US) | 2002-11-06 | — | — | EP | claimed |
| US-7009051-B2 | 4-(2-pyridyl) piperazines having 5HT7 receptor agonist activity | PFIZER INC (US) | 2006-03-07 | — | — | US | disclosed |
| US-20040014769-A1 | 4-(2-Pyridyl)piperazines having 5HT7 receptor agonist activity | PFIZER INC. | 2004-01-22 | — | — | US | disclosed |
| EP-1254905-B1 | 4-(2-Pyridyl)piperazines having 5HT7 receptor agonist activity | PFIZER PROD INC (US) | 2003-12-17 | — | — | EP | disclosed |
| US-20030008880-A1 | 4-(2-Pyridyl) piperizines having 5HT7 receptor agonist activity | PFIZER INC. | 2003-01-09 | — | — | US | disclosed |
| EP-1254905-A1 | 4-(2-Pyridyl)piperazines having 5HT7 receptor agonist activity | Pfizer Products Inc. (US) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014769-A1 | 4-(2-Pyridyl)piperazines having 5HT7 receptor agonist activity | HTR7, HTR1A, HTR2C | GLP1R 163/4885HTT 675/4885NPC1 2819/4885 |
| US-20030008880-A1 | 4-(2-Pyridyl) piperizines having 5HT7 receptor agonist activity | HTR7, HTR1A, HTR2C | GLP1R 187/4885HTT 768/4885NPC1 2899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.